Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Orphazyme A/S ADR (ORPH)

Orphazyme A/S ADR (ORPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,721
  • Shares Outstanding, K 35,312
  • Annual Sales, $ 0 K
  • Annual Income, $ -97,010 K
  • 60-Month Beta 1.68
  • Price/Sales 14.82
  • Price/Cash Flow N/A
  • Price/Book 1.12
Trade ORPH with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 04/05/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Sell
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5101 +70.55%
on 03/14/22
1.3720 -36.59%
on 03/10/22
-0.3500 (-28.69%)
since 02/28/22
3-Month
0.5101 +70.55%
on 03/14/22
2.7500 -68.36%
on 01/03/22
-1.7900 (-67.29%)
since 12/28/21
52-Week
0.5101 +70.55%
on 03/14/22
77.7700 -98.88%
on 06/10/21
-11.5200 (-92.98%)
since 03/26/21

Most Recent Stories

More News
Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344

BOTHELL, Wash., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces it has engaged hVIVO, a...

COCP : 2.34 (-0.43%)
ORPH : 0.8700 (-2.25%)
CytRx Comments on Orphazyme's Update on European Union Regulatory Review of Arimoclomol in Niemann-Pick Disease Type C

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented...

ORPH : 0.8700 (-2.25%)
CYTR : 0.0920 (unch)
CytRx Highlights Orphazyme's Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type C

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted...

ORPH : 0.8700 (-2.25%)
CYTR : 0.0920 (unch)
CytRx Comments on Quarterly Results and Recent Strategic Initiatives

CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories,...

IBRX : 5.71 (-1.38%)
ORPH : 0.8700 (-2.25%)
CYTR : 0.0920 (unch)
CytRx Highlights Orphazyme's Update on Productive Meeting with FDA Regarding Arimoclomol in Niemann-Pick Disease Type C

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories,...

ORPH : 0.8700 (-2.25%)
CYTR : 0.0920 (unch)
Promising New Developments Causing Some Biotech Stocks to Pull Away from Underperforming Peers

/PRNewswire/ -- USA News Group - Compared to the Dow Jones Industrial Average which has gained an impressive 10.6% through Q3 2021, and the S&P 500 and Nasdaq...

ONCY : 1.0200 (-0.97%)
SESN : 12.5760 (+7.29%)
CRXT : 0.0475 (-31.16%)
ORPH : 0.8700 (-2.25%)
JNJ : 154.24 (-0.29%)
Promising New Developments Causing Some Biotech Stocks to Pull Away from Underperforming Peers

FN Media Group Presents USA News Group News Commentary   Vancouver, BC –October 14, 2021 – USA News Group  –  Compared to the Dow Jones Industrial Average which has gained an impressive 10.6%...

ONCY : 1.0200 (-0.97%)
ONC.TO : 1.42 (+0.71%)
SESN : 12.5760 (+7.29%)
CRXT : 0.0475 (-31.16%)
ORPH : 0.8700 (-2.25%)
JNJ : 154.24 (-0.29%)
Biotech Winners Emerging Amid Sector’s Current Bearish Run

Compared to the Dow Jones Industrial Average which has gained an impressive 10.6% through Q3 2021, and ...

ONC.TO : 1.42 (+0.71%)
ORPH : 0.8700 (-2.25%)
JNJ : 154.24 (-0.29%)
SESN : 12.5760 (+7.29%)
CRXT : 0.0475 (-31.16%)
ONCY : 1.0200 (-0.97%)
AIM ImmunoTech Announces Clinical Trial Agreement for a Phase 2a Human Challenge Trial of Ampligen as a Potential Intranasal Prophylaxis Against Respiratory Viruses

The governing ethics committee and regulatory agency have met on the study protocol and plan to issue their response in Q4; AIM anticipates that the trial will commence shortly thereafter

LSE.LN : 8,620.000 (-0.58%)
AIM : 0.3700 (-0.08%)
ORPH : 0.8700 (-2.25%)
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Orphazyme, CorMedix, Koninklijke Philips, and Sesen Bio and Encourages Investors to Contact the Firm

NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders...

ORPH : 0.8700 (-2.25%)
CRMD : 4.74 (+1.94%)
PHG : 26.43 (+2.16%)
SESN : 12.5760 (+7.29%)

Business Summary

Orphazyme A/S is a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases. The company's product candidate includes Niemann-Pick disease Type C, Amyotrophic Lateral Sclerosis, sporadic Inclusion Body Myositis and Gaucher...

See More

Key Turning Points

3rd Resistance Point 1.0476
2nd Resistance Point 1.0023
1st Resistance Point 0.9362
Last Price 0.8700
1st Support Level 0.8248
2nd Support Level 0.7795
3rd Support Level 0.7134

See More

52-Week High 77.7700
Fibonacci 61.8% 48.2567
Fibonacci 50% 39.1400
Fibonacci 38.2% 30.0234
Last Price 0.8700
52-Week Low 0.5101

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar